Solid Execution and Momentum Entering 2026Annual sales of $3.5 billion, in line with guidanceOperating income of $516 million, including insurance settlement gain of $28 millionEBITDA(1) of $661 million, or 18.9% margin(1), including 0.8% increase from insurance settlement Strong operating cash flow of $557 million2023-2025 financial objectives met or exceeded and guidance set for 2026-2028Investment in a U.S. greenfield steel lattice facility to capitalize on the accelerating infrastructure spending trend ...

Haleon (NYSE:HLN) H2 2025 Earnings call February 25, 2026 03:45 AM ET Company ParticipantsBrian McNamara - CEOCeline Pannuti - Managing DirectorDavid Hayes - Managing DirectorDawn Allen - CFOEdward Lewis - PartnerJeremy Fialko - Head of Consumer Staples ResearchJo Russell - Head of Investor RelationsKarel Zoete - Head of Netherlands Equity ResearchOlivier Nicolai - Head of Consumer Staples ResearchSarah Simon - Managing DirectorTom Sykes - Managing Director of Equity ResearchWarren Ackerman - Managing Direc ...

Core Viewpoint - Church & Dwight reported strong fourth-quarter earnings that surpassed analyst expectations, leading to a 4% increase in share price intraday [1] Financial Performance - Adjusted earnings per share were $0.86, exceeding the consensus estimate of $0.84 [1] - Revenue reached $1.64 billion, aligning with expectations and reflecting a year-over-year increase of 3.9% [1] - Organic sales grew by 0.7%, improving to 1.8% when excluding the divested vitamin business [1] Margin and Cost Management - Adjusted gross margin expanded by 90 basis points to 45.5%, outperforming expectations [2] - Margin improvement was attributed to productivity initiatives, higher volumes, and a favorable product mix, which countered inflationary and tariff-related pressures [2] Strategic Decisions - The company completed the sale of its vitamin brands VITAFUSION and L'IL CRITTERS, incurring a one-time after-tax charge of $45.6 million [3] - The board approved a 4.2% increase in the quarterly dividend to $0.3075 per share, marking the 30th consecutive year of dividend growth [3] Future Outlook - For 2026, the company forecasts organic sales growth of 3% to 4% and adjusted EPS growth of 5% to 8% [4] - For the first quarter of 2026, organic sales growth is projected at approximately 3%, with adjusted EPS expected to be $0.92, slightly higher than the previous year [4]

Financial Data and Key Metrics Changes - For the third quarter, total sales were $790.1 million, up 6.6% year-over-year, with organic sales growth of 0.4% excluding Stuart Weitzman [19] - Consolidated gross margin was 42.7%, down 140 basis points compared to the previous year, driven by lower margins in both segments [20] - Operating earnings were $26.3 million, with an operating margin of 3.3% [22] Business Line Data and Key Metrics Changes - Brand portfolio sales increased 4.6% on an organic basis and 18.8% including Stuart Weitzman, with lead brands growing about 10% in North America [20] - Famous Footwear sales decreased by 2.2%, with comparable sales down 1.2% [15][20] - Sam Edelman and Allen Edmonds both delivered strong quarters with double-digit sales growth [9][10] Market Data and Key Metrics Changes - The international business showed marked strength, with significant market share gains in women's fashion footwear [8] - The premium brands performed well, while value-priced brands faced pressure [20] - The direct-to-consumer channels delivered growth and momentum, particularly in e-commerce [8] Company Strategy and Development Direction - The acquisition of Stuart Weitzman is seen as transformational, aligning with the company's focus on premium contemporary and direct-to-consumer business [5] - The company is working on integrating Stuart Weitzman to achieve break-even in 2026 and profitability thereafter [5][14] - Efforts are being made to establish new centers of excellence to drive structural cost savings and improve operational efficiency [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving better results in 2026, focusing on gross margin improvement and SG&A reductions [29][41] - The tariff environment is stabilizing, and mitigation efforts are beginning to take hold [15] - Management is optimistic about the performance of lead brands and the potential for organic growth in 2026 [42] Other Important Information - Inventory at the end of the quarter was $678 million, up $92 million year-over-year, with a portion attributed to Stuart Weitzman [23] - The company is addressing global excess inventory issues, with significant progress expected by entering 2026 [13] Q&A Session Summary Question: What is the opportunity for Stuart Weitzman going forward into 2026? - Management plans to achieve better results through gross margin improvement and SG&A reductions, with a focus on working closely with the Stuart Weitzman team [28] Question: How is the fashion side of the business performing, particularly in Famous Footwear? - Management noted success with premium brands and plans to build on this strength moving into 2026 [31] Question: What is the strategy for managing Stuart Weitzman's inventory? - The company is working on a multi-faceted approach to address aged inventory, with significant progress expected in the fourth quarter [35] Question: What are the expectations for gross margin improvement in 2026? - Management anticipates improvement in gross margin due to tariff mitigation efforts and better channel mix [41]

Core Viewpoint - Koninklijke Philips NV shares experienced a significant decline, marking the largest single-day drop since February, following cautious remarks from CEO Roy Jakobs at Citi's Global Healthcare Conference [1][2]. Group 1: Company Performance and Outlook - Philips anticipates organic sales growth to improve from 2% this year to 2026, but is "unlikely" to meet the 4.5% consensus forecast [2]. - The company reiterated its goal to enhance margins by 2026, although it warned that tariff headwinds are expected to nearly double next year [3]. - Philips expects comparative sales growth to accelerate towards mid-single-digit growth in 2026, supported by solid order momentum [6]. Group 2: Financial Results - For the third quarter of 2025, Philips reported adjusted earnings per share of 42 cents (0.36 euros), surpassing the consensus estimate of 37 cents [7]. - The company recorded quarterly sales of $5.03 billion (4.302 billion euros), aligning with market expectations [7]. Group 3: Market Conditions - The global hospital capital spending environment in 2026 is expected to be similar to 2025, with strong demand in the U.S. and solid performance in Europe and international markets, while conditions in China remain muted [4].

Core Insights - Solventum (SOLV) reported Q3 2025 adjusted EPS of $1.50, exceeding the Zacks Consensus Estimate of $1.43 by 4.9%, but down 8.5% year over year [1][7] - Revenues reached $2.1 billion, a 0.7% increase from the previous year, with organic sales growth of 2.7%, driven by strong performance in Dental Solutions and Health Information Systems [2][7] - The company raised its 2025 EPS outlook to $5.98-$6.08, anticipating organic sales growth at the higher end of 2-3% [12][7] Revenue Details - Total revenues were $2.1 billion, up 0.7% year over year, and beat the Zacks Consensus Estimate by 0.3% [2] - Organic sales growth was primarily driven by strong performance in Dental Solutions and Health Information Systems [2] Segmental Performance - **MedSurg**: Revenues totaled $1.21 billion, up 2.1% reportedly and 1.1% organically year over year, driven by NPWT growth and new product launches [4] - **Dental Solutions**: Revenues reached $340 million, an 8.4% increase year over year, driven by core restoratives and fluoride treatment adoption [5] - **Health Information Systems**: Revenues amounted to $345 million, up 5.9% reportedly and 5.6% organically, supported by revenue cycle management adoption [8] - **Purification and Filtration**: Revenues were $128 million, down 28.7% year over year, reflecting the divestment of this segment [8] Margin Analysis - Adjusted gross profit was $1.17 billion, down 1.9% year over year, with an adjusted gross margin of 55.8%, down approximately 150 bps [9] - Adjusted operating income totaled $431 million, down 9.3% year over year, with an adjusted operating margin of 20.6%, down approximately 220 bps [10] Financial Position - Solventum ended Q3 with cash and investments of $1.64 billion, a significant increase from $492 million in the previous quarter [11] - Total assets decreased to $13.97 billion from $15.07 billion in the previous quarter [11] - Cumulative net cash from operating activities was $274 million, down from $966 million in the year-ago period [11] 2025 Guidance - The company raised its sales guidance for 2025, expecting organic sales growth at the higher end of 2-3% [12] - Adjusted EPS is now projected to be in the range of $5.98-$6.08, up from the previous estimate of $5.88-$6.03 [12] Strategic Initiatives - Solventum is focused on operational discipline, supply-chain optimization, and cost-saving initiatives to offset inflationary pressures [14] - Progress on separation from 3M is ahead of schedule, enhancing operational control and service levels [15] - The successful divestment of the Purification and Filtration business has strengthened the balance sheet and provided flexibility for future growth [14]

Financial Performance - Solventum's total sales reached $2,096 million, with a reported increase of 0.7% year-over-year and an organic increase of 2.7% year-over-year[12] - MedSurg segment net sales were $1,206 million, reflecting a reported increase of 2.1% and an organic increase of 1.1% year-over-year[13, 17] - Dental Solutions segment net sales were $340 million, with a reported increase of 8.4% and an organic increase of 6.5% year-over-year[12, 24] - Health Information Systems segment net sales were $345 million, showing a reported increase of 5.9% and an organic increase of 5.6% year-over-year[12, 29] - Purification & Filtration segment net sales were $128 million, a reported decrease of 28.7% but an organic increase of 6.4% year-over-year, representing two months of sales before divestiture[12, 34] Profitability and Cash Flow - The company's GAAP operating margin was 80.6%, while the non-GAAP operating margin was 20.6%[13] - GAAP EPS was $7.22, and non-GAAP EPS was $1.50[13] - Cash from operations was $75 million, and free cash flow was negative $22 million[13] Guidance - The company expects organic sales growth of +2.0% to +3.0%, increasing to the high-end of range, or +2.5% to +3.5% excluding ~50bps of SKU-exit impact[39] - Adjusted EPS is expected to be $5.98 to $6.08, versus a prior range of $5.88 - $6.03[39] - Free cash flow is reduced to $150 million to $250 million from $450 million to $550 million due to the Purification & Filtration divestiture impact[39] - Net interest expense is estimated to be ~$360 million, with total non-operating expense around ~$400 million[40] Strategic Actions - The company completed the sale of the Purification & Filtration segment for approximately $4 billion, generating net proceeds of approximately $3.6 billion, with $2.7 billion used for debt reduction[34]

Core Insights - Novonesis achieved 8% organic sales growth in the first nine months of 2025 and has raised its full-year outlook to 7-8% from the previous 6-8% [1][4] - The company reported a strong adjusted EBITDA margin of 37.3%, despite facing significant currency headwinds [1][2] Sales Performance - Organic sales growth was broad-based at 8%, with a slight negative impact from exiting certain countries of approximately 1 percentage point [1][2] - The Food & Health segment saw 9% organic sales growth, while Planetary Health recorded 8% [2] - Emerging Markets outperformed with 12% organic sales growth, compared to 6% in Developed Markets [2] Financial Metrics - Adjusted EBITDA margin improved to 37.3%, up by 130 basis points, while adjusted net profit increased by 22% [2] - Net Interest-Bearing Debt (NIBD) to EBITDA ratio stood at 2.0x, with free cash flow before acquisitions reported at EUR 668.4 million [3] 2025 Outlook - The company expects organic sales growth for the full year to be between 7-8%, with mid-single-digit growth anticipated for Q4 [4] - Excluding the impact of exiting certain countries, organic sales growth is projected at 8-9% for the year [4] - The adjusted EBITDA margin is expected to be at the lower end of the 37-38% range [4]

Core Insights - The company reported an 8% organic sales growth in the first nine months, with strong profitability and cash flow, achieving a 37.3% adjusted EBITDA margin despite currency challenges [1][4] - For the fourth quarter, the company anticipates mid-single-digit organic sales growth and has raised its full-year organic sales growth expectation to 7-8% [1][4] - The company continues to execute its strategic priorities effectively, aiming to meet its 2030 targets [1] Sales Performance - Organic sales growth was 8%, with a Q3 growth of 6%, impacted by exiting certain countries by approximately 1 percentage point [4] - Food & Health segment achieved 9% organic sales growth, while Planetary Health recorded 8% [4] - Emerging Markets saw a 12% organic sales growth, compared to 6% in Developed Markets [4] Financial Metrics - Adjusted EBITDA margin improved to 37.3%, up by 130 basis points from Q3 [4] - Adjusted net profit increased by 22%, with a net debt to EBITDA ratio of 2.0x [4] - Free cash flow before acquisitions was EUR 668.4 million, significantly higher than EUR 361.3 million in Q3 [4] Future Outlook - The company now expects organic sales growth for 2025 to be between 7-8%, previously estimated at 6-8% [4] - Excluding the impact of exiting certain countries, the organic sales growth for the year is projected at 8-9% [4] - The adjusted EBITDA margin is anticipated to be at the lower end of the 37-38% range, factoring in currency headwinds [4]

Financial Performance - Q3 2025 - Net sales increased to $1483 million in 3Q25 from $1472.8 million in 3Q24 [11] - Adjusted EBITDA increased to $339.4 million in 3Q25 from $337 million in 3Q24, with a margin of 22.7% [11] - Adjusted diluted EPS increased to $2.51 in 3Q25 from $2.49 in 3Q24 [11] - Adjusted free cash flow increased to $174 million in 3Q25 from $125.5 million in 3Q24 [11] Segment Performance - Q3 2025 - Automation & Motion Control: Net sales increased slightly to $402 million, organic sales decreased by 1%, and adjusted EBITDA margin was 20.5% [24, 26] - Industrial Powertrain Solutions: Net sales increased by 2.8% to $662.3 million, organic sales increased by 1.6%, and adjusted EBITDA margin was 26.4% [28, 30] - Power and Efficiency Solutions: Net sales increased slightly to $432.7 million, organic sales increased by 0.8%, and adjusted EBITDA margin was 19% [32, 34] Updated 2025 Guidance - Sales are guided to approximately $5.96 billion [35] - Organic growth is expected to be low single digits [35] - Adjusted EBITDA margin is guided down to approximately 22% [35] - Adjusted EPS is guided to approximately $9.65 [35] - Free cash flow is now expected to be approximately $625 million [36] Tariff and Trade Policy Impacts - The unmitigated annual impact of tariffs is estimated to be approximately $175 million [37]